Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Escitalopram may not be appropriate if you: Are taking or have recently taken an MAO inhibitor (such as phenelzine, selegiline, or linezolid) Are taking pimozide Are taking citalopram (Celexa), as they are closely related and should not be used together Have a known allergy or hypersensitivity to escitalopram or citalopram Have a history of QT prolongation or are taking other medications that affect heart rhythm Are in the first trimester of pregnancy or breastfeeding, without first discussing risks with your doctor This is not a complete list of precautions, contraindications, or drug interactions
Endothelial cell death may be unfavorable for the structure of plaque because endothelial injury or death will promote lesional thrombosis [12, 13]
doi: 10.1503/cmaj.101281 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis Citation Deng R, Mei K, Song T, Huang J, Wu Y, Yu P, Yan Z and Liu X (2024) First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
Abstract Purpose of Review Obesity affects over than 600 million adults worldwide resulting in multi-organ complications and major socioeconomic impact
